PL2591094T3 - Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej - Google Patents

Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Info

Publication number: PL2591094T3
Authority: PL; Poland
Prior art keywords: cell culture; producing recombinant; recombinant adamts13; adamts13; producing
Prior art date: 2010-07-08

Application number

PL11738351T

Other languages

English (en)

Inventor

Leopold Grillberger

Manfred Reiter

Daniel Fleischanderl

Gregor Bramberger

Original Assignee

Baxalta GmbH

Baxalta Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-08

Filing date

2011-07-08

Publication date

2019-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2591094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-07-08 Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH

2019-02-28 Publication of PL2591094T3 publication Critical patent/PL2591094T3/pl

Links

238000004113 cell culture Methods 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL11738351T 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej PL2591094T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36263510P	2010-07-08	2010-07-08
PCT/US2011/043459 WO2012006594A1 (en)	2010-07-08	2011-07-08	Method of producing recombinant adamts13 in cell culture
EP11738351.3A EP2591094B1 (en)	2010-07-08	2011-07-08	Method of producing recombinant adamts13 in cell culture

Publications (1)

Publication Number	Publication Date
PL2591094T3 true PL2591094T3 (pl)	2019-02-28

Family

ID=44514323

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL16153131.4T PL3064508T5 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL19191438.1T PL3626736T3 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL11736502T PL2590998T3 (pl)	2010-07-08	2011-07-08	SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL11738351T PL2591094T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL18175765T PL3392271T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL16153131.4T PL3064508T5 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL19191438.1T PL3626736T3 (pl)	2010-07-08	2011-07-08	Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL11736502T PL2590998T3 (pl)	2010-07-08	2011-07-08	SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18175765T PL3392271T3 (pl)	2010-07-08	2011-07-08	Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Country Status (25)

Country	Link
US (8)	US8852888B2 (pl)
EP (7)	EP3064508B2 (pl)
JP (3)	JP5953502B2 (pl)
KR (4)	KR102007773B1 (pl)
CN (4)	CN103097409A (pl)
AU (6)	AU2011274467B2 (pl)
BR (1)	BR112013000515B1 (pl)
CA (2)	CA2804275A1 (pl)
CO (2)	CO6680636A2 (pl)
DK (4)	DK3626736T3 (pl)
EA (5)	EA202090067A3 (pl)
ES (5)	ES3037386T3 (pl)
FI (2)	FI3064508T4 (pl)
HR (4)	HRP20180136T1 (pl)
HU (4)	HUE046443T2 (pl)
IL (5)	IL223930A (pl)
MX (3)	MX339632B (pl)
NZ (2)	NZ605403A (pl)
PL (5)	PL3064508T5 (pl)
PT (4)	PT2590998T (pl)
SG (3)	SG10201809632XA (pl)
SI (4)	SI3626736T1 (pl)
TR (1)	TR201815211T4 (pl)
TW (4)	TWI670073B (pl)
WO (2)	WO2012006591A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2685503T3 (es)	2008-12-05	2018-10-09	Baxalta GmbH	Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
US8546548B2 (en)	2009-05-27	2013-10-01	Baxter International Inc.	Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en)	2010-05-26	2010-09-02	Takeda Pharmaceutical Company Limited	A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en)	2010-05-26	2014-07-08	Baxter International Inc.	Removal of serine proteases by treatment with finely divided silicon dioxide
EA202090067A3 (ru) *	2010-07-08	2020-07-31	Баксалта Инкорпорейтид	Способ получения рекомбинантного adamts13 в культуре клеток
CN103732244A (zh) *	2011-06-10	2014-04-16	巴克斯特国际公司	通过施用重组vwf治疗凝血疾病
US9030963B2 (en) *	2012-12-03	2015-05-12	Honeywell International Inc.	Analyzing a network topology
UY35343A (es) *	2013-02-26	2014-09-30	Bayer Healthcare Llc	Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US20140271622A1 (en) *	2013-03-14	2014-09-18	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US8956830B2 (en)	2013-03-14	2015-02-17	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US9677105B2 (en)	2013-03-14	2017-06-13	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
AR095196A1 (es) *	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
AU2013203062C1 (en) *	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13
EP3131929B1 (en) *	2014-04-16	2022-06-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (en) *	2014-06-13	2019-09-11	CSL Limited	Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) *	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3253884B1 (en) *	2015-02-05	2020-03-18	R.P. Scherer Technologies, LLC	Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) *	2015-03-26	2017-06-21	Chugai Pharmaceutical Co Ltd	Proceso de producción con iones de cobre controlados
TW202440903A (zh)	2015-08-04	2024-10-16	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法（一）
US11191818B2 (en)	2016-08-04	2021-12-07	Takeda Pharmaceutical Company Limited	Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) *	2017-03-16	2021-05-07	杨涛	一种用于人类多潜能干细胞的无血清培养基的配方
FI3648788T5 (fi)	2017-07-07	2024-09-09	Takeda Pharmaceuticals Co	Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja)	2017-07-07	2023-08-15	武田薬品工業株式会社	待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CA3094644A1 (en)	2018-03-21	2019-09-26	Baxalta Incorporated	Separation of vwf and vwf propeptide by chromatographic methods
EA202192140A1 (ru)	2019-02-01	2021-12-15	Такеда Фармасьютикал Компани Лимитед	СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
US11471497B1 (en)	2019-03-13	2022-10-18	David Gordon Bermudes	Copper chelation therapeutics
US10961500B1 (en)	2019-04-23	2021-03-30	Regeneron Pharmaceuticals, Inc.	Cell culture medium for eukaryotic cells
JP2022547556A (ja)	2019-09-11	2022-11-14	武田薬品工業株式会社	フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
US12661390B2 (en)	2019-10-04	2026-06-23	The Children's Medical Center Corporation	ADAMTS13 treatment to enhance graft survival
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
CA3169996A1 (en)	2020-02-04	2021-08-12	Takeda Pharmaceutical Company Limited	Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
EP4150045A1 (en) *	2020-05-12	2023-03-22	PBS Biotech, Inc.	Material transfer devices and related systems and methods
CN115835904A (zh)	2020-05-22	2023-03-21	武田药品工业有限公司	用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4767704A (en) *	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl)	1985-04-01	1986-11-03	Stichting Vrienden Van De Stic	Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
WO1986006096A1 (en)	1985-04-11	1986-10-23	The Children's Medical Center Corporation	Von willebrand factor
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
ATE542891T1 (de)	1994-11-10	2012-02-15	Baxter Healthcare Sa	Verfahren zur herstellung von biologischen produkten in protein-freier kultur
CA2211630A1 (en)	1995-02-23	1996-08-29	Quest International B.V.	Peptides for tissue and cell culture media
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
EP2221361A3 (en)	1996-08-30	2011-02-09	Life Technologies Corporation	Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6103529A (en)	1996-10-10	2000-08-15	Life Technologies, Inc.	Animal cell culture media comprising peptides derived from rice
WO1998041611A1 (en)	1997-03-20	1998-09-24	Regents Of The University Of Minnesota	Process for the continuous culture of cells
US5804420A (en)	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de)	1997-06-20	2001-02-26	Immuno Ag	Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en)	1997-06-20	2002-11-05	Baxter Aktiengesellschaft	Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en)	1997-12-15	2003-03-11	Hemasure Denmark A/S	von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en)	1998-05-29	2003-03-04	Genentech, Inc.	Mammalian cell culture process for producing glycoproteins
US6406909B1 (en)	1998-07-10	2002-06-18	Chugai Seiyaku Kabushiki Kaisha	Serum-free medium for culturing animal cells
AT409379B (de)	1999-06-02	2002-07-25	Baxter Ag	Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) *	1999-10-26	2001-05-08	Welfide Corp	生理活性物質の産生増強方法
US6926894B2 (en) *	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20050069979A1 (en) *	2001-11-28	2005-03-31	Steffen Zeng	Cell culture process
CN1296485C (zh) *	2002-01-17	2007-01-24	英国龙沙生物医药股份有限公司	能够产生蛋白质及能够在无谷氨酰胺的培养基上生长的谷氨酰胺营养缺陷型人类细胞
US20050084828A1 (en)	2003-10-21	2005-04-21	The University Of North Carolina At Chapel Hill	Apparatus and method for braille instruction
EP1593388A1 (en)	2004-05-05	2005-11-09	ZLB Behring GmbH	Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US7294484B2 (en) *	2004-08-27	2007-11-13	Wyeth Research Ireland Limited	Production of polypeptides
US20060094104A1 (en)	2004-10-29	2006-05-04	Leopold Grillberger	Animal protein-free media for cultivation of cells
US8273553B2 (en)	2004-11-02	2012-09-25	Ares Trading S.A.	Production of growth hormone in serum-free cell culture medium for mammalian cells
ES2361559T3 (es) *	2004-11-02	2011-06-20	Ares Trading S.A.	Medio de cultivo de células exento de suero para mamíferos.
US20070049557A1 (en)	2005-08-24	2007-03-01	Hashim Ahmed	Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
ES2474573T3 (es) *	2006-01-04	2014-07-09	Baxter International Inc	Medio de cultivo celular sin oligop�ptidos
US20070190057A1 (en) *	2006-01-23	2007-08-16	Jian Wu	Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) *	2006-07-14	2009-07-22	帝斯曼知识产权资产管理有限公司	改进的细胞培养方法
TW201516149A (zh) *	2006-09-13	2015-05-01	Abbvie Inc	細胞培養改良
US7960869B2 (en)	2006-09-22	2011-06-14	Siemens Industry, Inc.	Internal intelligence for remote operated relay
MX2009007145A (es)	2006-12-27	2009-08-27	Nektar Therapeutics Al Corp	Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
CA2679941C (en) *	2007-03-02	2016-09-20	Wyeth	Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) *	2007-09-28	2009-04-02	Osram Opto Semiconductors Gmbh	Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SI2574677T1 (sl) *	2007-12-27	2017-11-30	Baxalta GmbH	Procesi celične kulture
SG192471A1 (en)	2007-12-31	2013-08-30	Baxter Int	Substantially animal protein-free recombinant furin and methods for producing same
JP4458167B2 (ja) *	2008-01-11	2010-04-28	住友金属工業株式会社	熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en)	2008-03-19	2009-09-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Compounds for treating bacterial infections
AU2009236187B2 (en) *	2008-04-17	2012-08-02	Wyeth Llc	Methods for enhanced production of bone morphogenetic proteins
US8486699B2 (en) *	2008-05-23	2013-07-16	The United States Of America As Represented By The Secretary Of Agriculture	Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
NZ597727A (en)	2009-07-31	2013-08-30	Baxter Int	Cell culture medium for adamts protein expression
US8580554B2 (en)	2009-07-31	2013-11-12	Baxter International Inc.	Method of producing a polypeptide or virus of interest in a continuous cell culture
EA202090067A3 (ru)	2010-07-08	2020-07-31	Баксалта Инкорпорейтид	Способ получения рекомбинантного adamts13 в культуре клеток
TWI408228B (zh)	2010-10-29	2013-09-11	Univ Nat Chunghsing	用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

2011
- 2011-07-08 EA EA202090067A patent/EA202090067A3/ru unknown
- 2011-07-08 PL PL16153131.4T patent/PL3064508T5/pl unknown
- 2011-07-08 KR KR1020187024672A patent/KR102007773B1/ko active Active
- 2011-07-08 PL PL19191438.1T patent/PL3626736T3/pl unknown
- 2011-07-08 CA CA2804275A patent/CA2804275A1/en not_active Abandoned
- 2011-07-08 SG SG10201809632XA patent/SG10201809632XA/en unknown
- 2011-07-08 EA EA201792340A patent/EA035147B1/ru not_active IP Right Cessation
- 2011-07-08 CN CN2011800431007A patent/CN103097409A/zh active Pending
- 2011-07-08 KR KR1020187034201A patent/KR102027991B1/ko active Active
- 2011-07-08 CN CN2011800430945A patent/CN103097522A/zh active Pending
- 2011-07-08 US US13/179,386 patent/US8852888B2/en active Active
- 2011-07-08 ES ES19191438T patent/ES3037386T3/es active Active
- 2011-07-08 EP EP16153131.4A patent/EP3064508B2/en active Active
- 2011-07-08 ES ES11738351.3T patent/ES2694518T3/es active Active
- 2011-07-08 HU HUE16153131A patent/HUE046443T2/hu unknown
- 2011-07-08 DK DK19191438.1T patent/DK3626736T3/da active
- 2011-07-08 HR HRP20180136TT patent/HRP20180136T1/hr unknown
- 2011-07-08 MX MX2013000165A patent/MX339632B/es active IP Right Grant
- 2011-07-08 DK DK16153131.4T patent/DK3064508T4/da active
- 2011-07-08 PT PT117365023T patent/PT2590998T/pt unknown
- 2011-07-08 PT PT161531314T patent/PT3064508T/pt unknown
- 2011-07-08 NZ NZ605403A patent/NZ605403A/en unknown
- 2011-07-08 EP EP11738351.3A patent/EP2591094B1/en active Active
- 2011-07-08 WO PCT/US2011/043455 patent/WO2012006591A1/en not_active Ceased
- 2011-07-08 EP EP19191438.1A patent/EP3626736B1/en active Active
- 2011-07-08 KR KR1020137003278A patent/KR101924120B1/ko active Active
- 2011-07-08 SG SG2013000815A patent/SG186936A1/en unknown
- 2011-07-08 TW TW107130377A patent/TWI670073B/zh active
- 2011-07-08 HR HRP20250948TT patent/HRP20250948T1/hr unknown
- 2011-07-08 MX MX2013000166A patent/MX2013000166A/es active IP Right Grant
- 2011-07-08 US US13/179,399 patent/US9458222B2/en active Active
- 2011-07-08 AU AU2011274467A patent/AU2011274467B2/en active Active
- 2011-07-08 AU AU2011274470A patent/AU2011274470B2/en active Active
- 2011-07-08 SI SI201132134T patent/SI3626736T1/sl unknown
- 2011-07-08 ES ES16153131T patent/ES2761692T5/es active Active
- 2011-07-08 NZ NZ605404A patent/NZ605404A/en unknown
- 2011-07-08 HR HRP20181657TT patent/HRP20181657T1/hr unknown
- 2011-07-08 CN CN201710611592.4A patent/CN107286235A/zh active Pending
- 2011-07-08 PT PT191914381T patent/PT3626736T/pt unknown
- 2011-07-08 IL IL223930A patent/IL223930A/en active IP Right Grant
- 2011-07-08 HU HUE11738351A patent/HUE11738351T2/hu unknown
- 2011-07-08 PL PL11736502T patent/PL2590998T3/pl unknown
- 2011-07-08 BR BR112013000515-7A patent/BR112013000515B1/pt active IP Right Grant
- 2011-07-08 EA EA201390080A patent/EA035066B1/ru not_active IP Right Cessation
- 2011-07-08 WO PCT/US2011/043459 patent/WO2012006594A1/en not_active Ceased
- 2011-07-08 EA EA202090220A patent/EA202090220A3/ru unknown
- 2011-07-08 SI SI201131603T patent/SI2591094T1/sl unknown
- 2011-07-08 DK DK11738351.3T patent/DK2591094T3/en active
- 2011-07-08 EP EP25181050.3A patent/EP4628093A3/en active Pending
- 2011-07-08 ES ES11736502.3T patent/ES2664392T3/es active Active
- 2011-07-08 EA EA201390082A patent/EA029503B1/ru not_active IP Right Cessation
- 2011-07-08 SI SI201131818T patent/SI3064508T2/sl unknown
- 2011-07-08 TR TR2018/15211T patent/TR201815211T4/tr unknown
- 2011-07-08 IL IL286298A patent/IL286298B/en unknown
- 2011-07-08 DK DK11736502.3T patent/DK2590998T3/en active
- 2011-07-08 FI FIEP16153131.4T patent/FI3064508T4/fi active
- 2011-07-08 SG SG2013000799A patent/SG186935A1/en unknown
- 2011-07-08 TW TW100124395A patent/TWI617575B/zh active
- 2011-07-08 TW TW100124394A patent/TWI609890B/zh active
- 2011-07-08 HR HRP20192089TT patent/HRP20192089T4/hr unknown
- 2011-07-08 KR KR1020137003277A patent/KR101894604B1/ko active Active
- 2011-07-08 SI SI201131409T patent/SI2590998T1/en unknown
- 2011-07-08 EP EP21170129.7A patent/EP3909977A1/en active Pending
- 2011-07-08 HU HUE11736502A patent/HUE038193T2/hu unknown
- 2011-07-08 EP EP11736502.3A patent/EP2590998B1/en active Active
- 2011-07-08 MX MX2015014216A patent/MX353409B/es unknown
- 2011-07-08 CA CA2805557A patent/CA2805557A1/en not_active Abandoned
- 2011-07-08 EP EP18175765.9A patent/EP3392271B8/en active Active
- 2011-07-08 CN CN201711432166.0A patent/CN108060154A/zh active Pending
- 2011-07-08 HU HUE19191438A patent/HUE072809T2/hu unknown
- 2011-07-08 FI FIEP19191438.1T patent/FI3626736T3/fi active
- 2011-07-08 TW TW105121378A patent/TWI646972B/zh active
- 2011-07-08 PT PT11738351T patent/PT2591094T/pt unknown
- 2011-07-08 JP JP2013518869A patent/JP5953502B2/ja active Active
- 2011-07-08 ES ES18175765T patent/ES2875772T3/es active Active
- 2011-07-08 JP JP2013518871A patent/JP6138683B2/ja active Active
- 2011-07-08 PL PL11738351T patent/PL2591094T3/pl unknown
- 2011-07-08 PL PL18175765T patent/PL3392271T3/pl unknown
2012
- 2012-12-27 IL IL223929A patent/IL223929A/en active IP Right Grant
2013
- 2013-02-07 CO CO13025476A patent/CO6680636A2/es unknown
- 2013-02-07 CO CO13025488A patent/CO6690745A2/es unknown
2014
- 2014-07-23 US US14/339,319 patent/US9409971B2/en active Active
- 2014-09-03 US US14/476,580 patent/US20150056657A1/en not_active Abandoned
2015
- 2015-07-27 AU AU2015207811A patent/AU2015207811B2/en active Active
2016
- 2016-07-01 US US15/201,125 patent/US9834591B2/en active Active
2017
- 2017-05-09 US US15/591,022 patent/US10100099B2/en active Active
- 2017-08-01 JP JP2017149409A patent/JP2017217004A/ja active Pending
- 2017-10-30 IL IL255327A patent/IL255327B/en active IP Right Grant
2018
- 2018-01-10 AU AU2018200206A patent/AU2018200206B2/en active Active
- 2018-09-07 US US16/125,141 patent/US10822394B2/en active Active
2020
- 2020-03-15 IL IL273304A patent/IL273304B/en unknown
- 2020-05-29 AU AU2020203565A patent/AU2020203565B2/en active Active
- 2020-10-30 US US17/086,072 patent/US11780904B2/en active Active
2022
- 2022-01-05 AU AU2022200035A patent/AU2022200035A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20180130587A (ko)	2018-12-07
EP4628093A2 (en)	2025-10-08
US20120035110A1 (en)	2012-02-09
HUE038193T2 (hu)	2018-09-28
JP2013538046A (ja)	2013-10-10
US9409971B2 (en)	2016-08-09
EA202090067A3 (ru)	2020-07-31
IL286298A (en)	2021-10-31
BR112013000515A2 (pt)	2016-05-17
HRP20250948T1 (hr)	2025-10-10
JP2013533748A (ja)	2013-08-29
IL273304B (en)	2021-09-30
CO6680636A2 (es)	2013-05-31
MX2013000165A (es)	2013-06-05
PL3064508T5 (pl)	2024-04-08
US20190085052A1 (en)	2019-03-21
DK2591094T3 (en)	2018-11-26
IL255327B (en)	2020-04-30
JP6138683B2 (ja)	2017-05-31
SG10201809632XA (en)	2018-12-28
MX353409B (es)	2018-01-11
SI3626736T1 (sl)	2025-10-30
NZ605403A (en)	2014-10-31
HRP20192089T4 (hr)	2023-04-28
EA201792340A3 (ru)	2018-07-31
KR20180099922A (ko)	2018-09-05
DK3064508T4 (da)	2023-04-11
KR20130091328A (ko)	2013-08-16
SG186935A1 (en)	2013-02-28
TWI670073B (zh)	2019-09-01
MX339632B (es)	2016-06-02
EP2590998B1 (en)	2017-11-15
CN108060154A (zh)	2018-05-22
PT2590998T (pt)	2018-02-13
PT3626736T (pt)	2025-08-11
SI2590998T1 (en)	2018-06-29
HUE11738351T2 (hu)	2019-03-28
TW201206953A (en)	2012-02-16
US20170008948A1 (en)	2017-01-12
AU2018200206A1 (en)	2018-04-05
PT3064508T (pt)	2019-12-05
KR101924120B1 (ko)	2018-11-30
HRP20181657T1 (hr)	2019-03-08
IL223929A (en)	2017-11-30
US8852888B2 (en)	2014-10-07
NZ605404A (en)	2014-08-29
EP2591094B1 (en)	2018-09-05
EA202090220A3 (ru)	2020-08-31
KR101894604B1 (ko)	2018-09-03
WO2012006591A1 (en)	2012-01-12
JP2017217004A (ja)	2017-12-14
SI2591094T1 (sl)	2018-12-31
ES2875772T3 (es)	2021-11-11
HRP20180136T1 (hr)	2018-04-06
PT2591094T (pt)	2018-11-20
US11780904B2 (en)	2023-10-10
AU2011274470B2 (en)	2015-08-13
EP3392271B1 (en)	2021-05-05
US20180044405A1 (en)	2018-02-15
SI3064508T2 (sl)	2023-05-31
CA2805557A1 (en)	2012-01-12
IL255327A0 (en)	2017-12-31
TW201204744A (en)	2012-02-01
EA029503B1 (ru)	2018-04-30
WO2012006594A1 (en)	2012-01-12
US20210115110A1 (en)	2021-04-22
IL286298B (en)	2022-08-01
SI3064508T1 (sl)	2019-12-31
EA035147B1 (ru)	2020-05-06
EA202090067A2 (ru)	2020-04-30
US9458222B2 (en)	2016-10-04
EP3064508B2 (en)	2023-03-15
PL3626736T3 (pl)	2025-10-13
AU2015207811B2 (en)	2017-10-19
US10100099B2 (en)	2018-10-16
TWI646972B (zh)	2019-01-11
HUE072809T2 (hu)	2025-12-28
KR102007773B1 (ko)	2019-08-06
EP3064508A1 (en)	2016-09-07
EA035066B1 (ru)	2020-04-23
EA201792340A2 (ru)	2018-02-28
CN103097409A (zh)	2013-05-08
EP2591094A1 (en)	2013-05-15
EP3626736A1 (en)	2020-03-25
IL273304A (en)	2020-04-30
HUE046443T2 (hu)	2020-03-30
AU2020203565A1 (en)	2020-06-18
AU2018200206B2 (en)	2020-05-28
PL3064508T3 (pl)	2020-02-28
TWI609890B (zh)	2018-01-01
US20120034674A1 (en)	2012-02-09
DK2590998T3 (en)	2018-02-12
JP2016025873A (ja)	2016-02-12
TW201900207A (zh)	2019-01-01
BR112013000515B1 (pt)	2021-11-03
KR20130091329A (ko)	2013-08-16
IL223930A (en)	2017-01-31
ES2664392T3 (es)	2018-04-19
AU2011274467B2 (en)	2015-01-15
TR201815211T4 (tr)	2018-11-21
TW201637665A (zh)	2016-11-01
DK3064508T3 (da)	2019-11-25
EP3909977A1 (en)	2021-11-17
EA201390082A1 (ru)	2013-06-28
AU2020203565B2 (en)	2021-09-30
JP5953502B2 (ja)	2016-07-20
AU2011274470A1 (en)	2013-01-24
CN103097522A (zh)	2013-05-08
US10822394B2 (en)	2020-11-03
EA201390080A1 (ru)	2013-06-28
EP3626736B1 (en)	2025-06-11
PL3392271T3 (pl)	2021-11-15
EP3392271B8 (en)	2021-06-16
AU2011274467A1 (en)	2013-01-24
JP6284919B2 (ja)	2018-02-28
CN107286235A (zh)	2017-10-24
AU2022200035A1 (en)	2022-01-20
PL2590998T3 (pl)	2018-05-30
ES2761692T5 (es)	2023-07-05
ES2761692T3 (es)	2020-05-20
AU2015207811A1 (en)	2015-08-20
MX2013000166A (es)	2013-06-05
EP3064508B1 (en)	2019-08-28
HRP20192089T1 (hr)	2020-03-20
US20150018525A1 (en)	2015-01-15
CO6690745A2 (es)	2013-06-17
CA2804275A1 (en)	2012-01-12
FI3626736T3 (fi)	2025-08-22
FI3064508T4 (fi)	2023-04-25
KR102027991B1 (ko)	2019-10-02
ES3037386T3 (en)	2025-10-01
ES2694518T3 (es)	2018-12-21
EA202090220A2 (ru)	2020-05-31
DK3626736T3 (da)	2025-08-18
TWI617575B (zh)	2018-03-11
EP4628093A3 (en)	2025-12-10
SG186936A1 (en)	2013-02-28
US20150056657A1 (en)	2015-02-26
BR112013000512A2 (pt)	2016-05-17
EP2590998A1 (en)	2013-05-15
US9834591B2 (en)	2017-12-05
EP3392271A1 (en)	2018-10-24

Publication	Publication Date	Title
HRP20181657T1 (hr)	2019-03-08	Postupak proizvodnje rekombinantog adamts13 u kulturi stanica
IL267629A (en)	2019-08-29	A method for eukaryotic cell culture
GB2491209B (en)	2013-08-21	Solar cell and method for producing same
ZA201707452B (en)	2021-03-31	Cell culture compositions and methods for polypeptide production
PT2459697T (pt)	2019-01-21	Método de produção de um polipeptídeo ou vírus de interesse numa cultura de células contínua
IL222454A0 (en)	2012-12-31	Improved cell cultivation process
EP2635690A4 (en)	2013-11-27	COMPOSITIONS AND METHOD FOR PRODUCING FERMENTABLE SUGAR
SG10201503666UA (en)	2015-06-29	Apparatus and methods for cell culture
EP2729561A4 (en)	2015-06-24	CELL CULTURE METHOD
EP2700707A4 (en)	2014-12-03	CELL CULTURE METHOD AND CELL CULTURE KIT
PL2554656T3 (pl)	2018-10-31	Sposób hodowli drożdży
GB201113641D0 (en)	2011-09-21	Cell culture support and cell culture method
EP2702615A4 (en)	2014-09-03	SOLAR CELL AND MANUFACTURING METHOD THEREFOR
EP2383331A4 (en)	2012-06-27	METHOD FOR PRODUCING A CELL CULTURAL FRAME
GB201005736D0 (en)	2010-05-19	Electrolysis cell and method of operation
GB201020075D0 (en)	2011-01-12	Mammalian cell transformation method
IL223178A0 (en)	2013-02-03	Photovoltaic cell and method of its manufacture
GB201007855D0 (en)	2010-06-23	Bioreactor for the culture of cells
GB201007863D0 (en)	2010-06-23	Bioreactor for cell culture
GB201120446D0 (en)	2012-01-11	Mammalian cell transformation method